Category: Latest News

Multiple sclerosis (MS) was front and center when neurologists from across the nation gathered in San Diego in April for the annual meeting of the American Academy of Neurology (AAN). More than 180 research presentations at the meeting focused on investigational and approved medications for MS, means of monitoring the condition, and strategies for improving quality of life for people with MS.

The Multiple Sclerosis Association of America (MSAA) is honored to bring MS community members together for the 11th Improving Lives Benefit on Wednesday, May 14, 2025 at 6:15 PM ET at the Barnes Foundation in Philadelphia, PA. This impactful program will also be livestreamed, allowing individuals from across the country to participate from the comfort of their homes.

The researchers and clinicians who gathered in late February in West Palm Beach, Florida, for the 2025 ACTRIMS Forum shared data and insights on a range of promising investigational therapies, such as Bruton’s tyrosine kinase inhibitors and chimeric antigen receptor T-cell therapy.

The Multiple Sclerosis Association of America (MSAA) proudly recognizes March as MS Awareness Month, presenting various special initiatives and programs to support the MS community. This month’s awareness campaign, “Empowered from the Start with MSAA,” focuses on providing resources and self-advocacy strategies for individuals who are newly diagnosed with MS.

A new year promises to bring a wealth of new insights into the nature and management of multiple sclerosis (MS). The study summaries included in this edition of “What’s New in MS Research” highlight the broad spectrum of inquiry that is driving the progress to develop better treatments against the disease.

The world’s leading experts in multiple sclerosis (MS) gathered in Copenhagen, Denmark in September 2024 to share the results of their latest research into the causes, course, and treatment of the disease. That gathering, the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), showcased encouraging findings from a number of vital studies.

The Multiple Sclerosis Association of America (MSAA) is pleased to announce that we are the recipients of a Fall 2024 Digital Health Award! We are proud to have been presented with a Silver Digital Health Award in the Web-based Digital Health category

People with relapsing and progressive forms of MS now can receive Ocrevus® (ocrelizumab) via intravenous infusion or Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq) by subcutaneous injection.

It wasn’t just the music that had multiple sclerosis (MS) researchers, clinicians, and advocates in an upbeat mood when they gathered in Nashville from May 29th through June 1st for the Consortium of Multiple Sclerosis Centers’ (CMSC) 2024 Annual Meeting. Rather, the positive vibes reflected the many encouraging developments in MS research reported during the CMSC’s multi-day gathering.

The Multiple Sclerosis Association of America (MSAA) is proud to announce that we are the recipients of an APEX Award for Excellence from the 36th Annual APEX Awards, as well as a Merit Award from the 31st Annual National Health Information Awards!